Mucocutaneous Lymph Node Syndrome
Recent clinical, regulatory, research and industry developments relating to this disease.
The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19.
Multisystem Inflammatory Syndrome in Children in New York State.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes4
- Coronary Aneurysm1
- Mucocutaneous Lymph Node Syndrome1
- Symptom Assessment1
- Systemic Inflammatory Response Syndrome1
Leading journals5
- Arthritis & rheumatology (Hoboken, N.J.)2
- Circulation2
- Cell1
- JAMA1
- The New England journal of medicine1
Leading researchers8
- Burns JC3
- Newburger JW3
- Baddour LM2
- Baltimore RS2
- Ferrieri P2
- Friedman KG2
- Henderson LA2
- Shulman ST2
Affiliations (unnormalised)6
- American College of Rheumatology1
- Bambino Gesù Children's Hospital1
- Boston Children's Hospital1
- Boston Children's Hospital and Brigham and Women's Hospital1
- Boston Children's Hospital and Harvard Medical School1
- Center for Regenerative Medicine1
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Mucocutaneous lymph node syndrome is an acute febrile condition of infants and young children marked by inflammation of the mucous membranes and skin, together with swelling of the cervical lymph nodes. The described features include fever, conjunctival congestion, reddening of the lips and oral cavity, prominent tongue papillae, and edema or erythema of the extremities. It is also referred to in the grounding as Kawasaki disease.
The grounding characterizes the disease as an acute self-limited vasculitis of childhood. The literature supplied also links it to inflammatory features involving cytokines and immunoglobulins, and notes that intravenous gamma globulin is used in management, consistent with an immune-mediated inflammatory process. Coronary artery aneurysms or ectasia can develop in untreated cases, indicating vascular involvement.
The grounding identifies infants and young children as the affected population. Untreated disease is associated with a substantial risk of coronary artery aneurysms or ectasia, but no additional predisposing factors are provided in the supplied material.
The supplied guidance describes treatment with intravenous gamma globulin (IVIG) and use of echocardiography to guide management in children meeting fever and clinical criteria. The literature also emphasizes diagnosis, treatment, and long-term management, including attention to coronary complications. No other treatment classes are supported by the grounding.
AI-generated summary grounded in MeSH and 3 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
An acute, febrile, mucocutaneous condition accompanied by swelling of cervical lymph nodes in infants and young children. The principal symptoms are fever, congestion of the ocular conjunctivae, reddening of the lips and oral cavity, protuberance of tongue papillae, and edema or erythema of the extremities.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.